Loading patent…
AssigneeBioNumerik Pharmaceuticals, Inc.
InventorFrederick H. Hausheer
Estimating the term…
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.
1) A method for increasing survival time in a patient with cancer, wherein said cancer, either:
3) A method of increasing survival time in a patient with non-small cell lung carcinoma, wherein the non-small lung carcinoma, either:
4) A method of increasing survival time in a patient with adenocarcinoma, wherein the adenocarcinoma, either:
17) A kit comprising a Formula (I) compound for administration, and instructions for administering said Formula (I) compound to a patient with cancer in an amount sufficient to cause an increase in the survival time of said patient with cancer who is receiving a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either:
20) A kit comprising a Formula (I) compound for administration, and instructions for administering said Formula (I) compound to a patient with non-small cell lung carcinoma in an amount sufficient to cause an increase in the survival time of said patient who is receiving a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either:
21) A kit comprising a Formula (I) compound for administration, and instructions for administering said Formula (I) compound to a patient with adenocarcinoma in an amount sufficient to cause an increase in the survival time of said patient who is receiving a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either:
34) A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from cancer treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
36) A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from non-small cell lung carcinoma treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
37) A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from adenocarcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
39) A method for potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from cancer, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
41) A method for potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from non-small cell lung carcinoma, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
42) A method for potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from adenocarcinoma, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
43) A method for promoting the arrest or retardation of tumor progression in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
45) A method for promoting the arrest or retardation of tumor progression in a patient suffering from non-small cell lung carcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound and the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
46) A method for promoting the arrest or retardation of tumor progression in a patient suffering from adenocarcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
47) A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
49) A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from non-small cell lung carcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
50) A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from adenocarcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, and wherein the administration of said Formula (I) compound occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said Formula (I) compound, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically sufficient dosages.
51) A method for increasing the survival time while concomitantly affecting hematological function in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a Formula (I) compound to said patient, the effect on hematological function is selected from the group consisting of:
Dependencies are inferred from the claim text.